Johnson and Johnson News

The single, easiest way to keep track of all the stocks that matter... Your own personalized stock watchlist! It's a 100% FREE Motley Fool service... The wealth-building power of compound interest will never cease to amaze me.

Though Janssen Korea says it is confident it will resolve its manufacturing issues, product recall and suspensions could be followed by lawsuits and imprisonment.

The study saw more than 400 patient groups from 39 different countries assessing 30 'medtech' companies on their ability to meet patient expectations.

The key to making smart investment decisions on stocks reporting earnings is to anticipate how they'll do before they announce results, leaving you fully prepared to respond quickly to whatever inevitable surprises arise.

Sheri S. McCoy, the chief executive officer and a director of Avon Products, will deliver the keynote address at Stonehill College's 62nd Commencement on Sunday, May 19.

The wound care market may not be the most exciting biotech niche on the surface, but the multi-billion dollar industry's need for innovation has created an opportunity for smaller companies operating in the space.

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today! Johnson and Johnson could be sourcing commercial quantities of poppies outside Tasmania in 2015.

Johnson & Johnson, the world's biggest maker of health-care products, said it will stop selling metal-on-metal and ceramic-on-metal hip replacements as demand wanes for the devices and U.S. regulators seek new rules.

Research by media monitoring company Precise, published in March 2013 says that consumers are more likely to view FMCG companies favourably if they develop a recognisable corporate brand.

EDANA, the Association Serving the Nonwovens and Related Industries, has announced its new board of governors for 2013-2015, the most international board ever the group says with representatives from across Europe, the Middle East, United States and Asia.

With interest rates near zero, investors have been desperately seeking yield. As a result, one of the hottest trades for investors over the last three to four years has been buying large companies that pay high dividends.

A small implantable device, an artificial pancreas would continuously monitor blood-sugar levels and release insulin as needed in patients with Type 1 diabetics.

In Part I of "Johnson & Johnson: At The Crossroads", consideration was given to whether a dividend growth rate of 8.2% was sustainable if net income growth rate remained around the projected 6%. It was determined that this gap between dividend and net income growth rates was likely sustainable for at least the next 15 years.

After listening to the media trash JP Morgan's Jamie Dimon for the past year, and following the recent uproar caused by proxy firm recommendations that shareholders vote to separate the company's Chairman and CEO functions, I simply cannot sit by any longer without speaking up in Dimon's defense.

When shopping in any store that carries national brands, it's virtually impossible to remember which ones you're not supposed to buy for which reasons.

Johnson & Johnson won U.S. approval to use its rheumatoid arthritis drug Simponi to treat patients suffering from a moderate to severe inflammatory bowel disease.

Assessing whether a stock is a "value play" or a "value trap" has become a popular hobby for financial writers.

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today! In one of the more curious departures of a high-ranking FDA official, Leona Brenner-Gati unexpectedly resigned from the agency earlier this month and did so immediately for unexplained personal reasons.

Turning today to week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, the largest outflow was seen in the Health Care Select Sector SPDR Fund , which shed 22.3 million shares, or a 13.4% decrease week over week.

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today! Johnson & Johnson unit Janssen Research and Development LLC said the U.S. Food and Drug Administration has granted priority review to its new drug application for simeprevir, its investigational treatment of genotype 1 chronic hepatitis C in adult patients ... (more)